# A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

> **NCT07189065** · PHASE2 · RECRUITING · sponsor: **Guangzhou Lupeng Pharmaceutical Company LTD.** · enrollment: 150 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma (DLBCL)

## Interventions

- **DRUG:** Rocbrutinib
- **DRUG:** Bendamustine
- **DRUG:** Rituximab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT07189065
- **Lead sponsor:** Guangzhou Lupeng Pharmaceutical Company LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-27
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07189065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07189065, "A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07189065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*